Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arrowhead Pharmaceuticals (ARWR)

Arrowhead issues $700 million of 0% convertible senior notes due 2032

Neutral Impact 4 of 5 financing Written later

Arrowhead Pharmaceuticals issued $700 million of 0.00% convertible senior notes due January 15, 2032, including $75 million from the underwriters' full exercise of their over-allotment option. The company also spent approximately $47.9 million on capped call transactions, which are expected to reduce potential dilution from future conversions of the notes.

Key points

  • Notes issued January 12, 2026: $700 million principal, 0.00% interest rate, maturing January 15, 2032
  • Initial conversion price of approximately $87.07 per share; the company may settle conversions in cash, shares or a combination
  • Capped call transactions cost approximately $47.9 million, with a cap price of approximately $119.33 per share
  • Company may redeem notes on or after January 16, 2029 if the stock exceeds 130% of the conversion price under specified conditions

The filing

CompanyArrowhead Pharmaceuticals (ARWR)
Form8-K, current report
Filed with the SECJan 12, 2026, 5:00 PM ET
Accession number0001193125-26-010582

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:17 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.